PTPA and triple-negative breast carcinoma: Using immunoprecipitation in triple negative breast cancer cells treated with LB100, a PP2A inhibitor, we demonstrated that LB100 significantly reduced the association between PP2A and CDC25B (Supplementary Figure S2B).